ClinicalTrials.gg
RecruitingNCT07610720Updated May 28, 2026

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

A Phase 2 interventional study of Dalpiciclib and Trastuzumab (Herceptin) in Advanced/Metastatic Breast Cancer and HER2-Positive Metastatic Breast Cancer, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know · 12 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
57
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies testing dalpiciclib in Breast Neoplasms — 30 open to participants now, 35 under way, 4 of them phase 3. dalpiciclib · Breast Neoplasms.

Planned enrollment
29th of 49
57 · median 72
Started
2026
with 5 others
Phase 2
31 of 49
22 open now
Primary completion
2028-11
later than 27 of 34 live
Registered
45th of 49
by date

Among the 49 studies testing dalpiciclib in Breast Neoplasms, this one is the 29th largest by planned enrollment, is one of 6 that started in 2026, is one of 31 in phase 2, reaches primary completion later than 27 of the 34 other live ones, and was the 45th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 49 studies testing dalpiciclib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

About dalpiciclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing dalpiciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Read the detailed description

This is a multicenter, single-arm, open-label, phase II clinical trial evaluating the efficacy and safety of dalpiciclib (a novel oral CDK4/6 inhibitor) combined with anti-HER2 therapy and endocrine therapy as maintenance treatment in patients with hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer who have completed induction systemic therapy without disease progression.

Triple-positive (HR+/HER2+) metastatic breast cancer represents a unique subtype requiring dual pathway inhibition. Current standard first-line induction therapy includes taxane-based chemotherapy combined with trastuzumab and pertuzumab (THP) or pyrotinib (THPy), followed by maintenance with anti-HER2 therapy plus endocrine therapy. However, approximately 50% of patients progress within 18 months during maintenance therapy.

This study explores the addition of dalpiciclib to standard anti-HER2 and endocrine maintenance therapy to prolong progression-free survival. Dalpiciclib, the first domestically developed CDK4/6 inhibitor in China, has demonstrated favorable efficacy and a manageable safety profile in HR+/HER2- advanced breast cancer, with a lower incidence of febrile neutropenia and no observed interstitial lung disease.

03

Conditions studied

  • Advanced/Metastatic Breast Cancer
  • HER2-Positive Metastatic Breast Cancer

Browse trials for

Keywords

  • Dalpiciclib
  • Dalpiciclib Plus Anti-HER2 Therapy and Endocrine Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 18 to 75 years with confirmed or locally advanced unresectable breast cancer.
  2. Hormone receptor (HR)-positive and -positive.
  3. Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of systemic anti-tumor therapy.
  4. Performance Status: 0-1.

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic active or extensive .
  2. History of Grade 3 or 4 allergic reaction related to the study drugs.
  3. Currently receiving other anti-tumor therapies.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Dalpiciclib + Endocrine Therapy + Trastuzumab ± Pertuzumab or Pyrotinib

    Drug: Dalpiciclib · Drug: Trastuzumab (Herceptin) · Drug: Pertuzumab · Drug: Pyrotinib · Drug: Endocrine Therapy 1

Interventions

  • Oral CDK4/6 inhibitor (dose modification permitted for toxicity management)

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subcutaneous, 600mg Q3W; IV: 8mg/kg (loading) → 6mg/kg Q3W

  • IV: 840mg (loading) → 420mg Q3W

  • 240mg qd Week 1 → 320mg qd from Week 2 (max dose); loperamide prophylaxis for diarrhea

  • DrugEndocrine Therapy 1

    Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)

This study also gives FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time from enrollment to radiographic disease progression (per RECIST 1.1) or death from any cause, whichever occurs first

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.

Secondary outcomes

  1. Objective Response Rate (ORR)

    Proportion of patients achieving Complete Response (CR) or Partial Response (PR) per RECIST 1.1

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.

  2. Overall Survival (OS)

    Time from enrollment to death from any cause

    Time frame: From randomization until the end of the study (approximately 36 months)

  3. Safety and Tolerability

    Incidence, type, severity, and relationship of adverse events (AEs) graded by NCI CTCAE v5.0

    Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.

  4. Disease-Specific Quality of Life Assessed by EORTC QLQ-BR45

    Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer-Specific Module (EORTC QLQ-BR45). The EORTC QLQ-BR45 contains 45 items divided into functional and symptom scales evaluating breast cancer-specific issues and treatment side effects. All scales range in score from 0 to 100. A higher score for a functional scale represents a higher/healthy level of functioning, whereas a higher score for a symptom scale represents a higher level of breast cancer-related symptomatology or treatment-related problems.

    Time frame: From the date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.

  5. Quality of Life Assessed by EORTC QLQ-C30

    Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 consists of 30 items incorporating 5 functional scales, 3 symptom scales, a global health status scale, and 6 single items. All scales and single-item measures range in score from 0 to 100. A higher score for a functional scale or global health status represents a higher/healthy level of functioning, whereas a higher score for a symptom scale/item represents a higher level of symptomatology or problems.

    Time frame: From the date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 2 years after the last participant completes treatment.

07

Study locations

1 of 1 sites recruiting
  • Sun yat-Sen University Cancer Center, Guangzhou, Yuexiu District
    Guangdong, GUANGZHOU 510060, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Nov 2028, 29 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 29 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 28, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2029
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07610720
Responsible party
Jia-Jia Huang (Department of Medical Oncology Professor, Principal Investigator, Chief Physician, Sun Yat-sen University) — Principal investigator
First posted
May 28, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2029 (estimated)
Last update
May 28, 2026

Study contacts

Chen Doctor Chen, PhD / Doctorate
Contact
chenmt@sysucc.org.cn
02087341812

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalpiciclib

Start the discussion